Immunicon Rasies $11 Million for New Cancer Treatments

Want to share this story?

San Diego based Immunicom announced it has raised $11 million in a Series B investment round to fund its ongoing triple-negative breast cancer clinical trial.

It has not named investors in this funding round. It’s total capital raised so far is $20 million.

“Proceeds from this financing will help fund the 170-patient, randomized, multi-center, triple-negative breast cancer clinical trial we began May 31, while also fueling continued expansion of Immunicom’s global strategic partnerships,” said Amir Jafri, the company’s Founder and CEO, in a statement.

In addition to focusing on aggressive and non-aggressive cancers, Immunicon also develops innovative, non-pharmaceutical approaches for treating inflammatory diseases, and autoimmune diseases. The health-focused startup recently received an FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating late-stage metastatic cancers.